Insider · CIK 0001322731
Rahul Singhvi
Files at CDXS (CODEXIS, INC.), KAPA (Kairos Pharma, LTD.). First filing -, latest -.
Rahul Singhvi files SEC Form 4 as director at CDXS (CODEXIS, INC.), and also at KAPA (Kairos Pharma, LTD.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Rahul Singhvi has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | CDXS CODEXIS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +66,350 | $0.00 | $0 | 66,350 | Jun 18, 2026 |
| Oct 8, 2025 | KAPA Kairos Pharma, LTD. | AGrant or award COMMON STOCK | +19,084 | $0.00 | $0 | 49,204 | Nov 26, 2025 |
| Jun 10, 2025 | CDXS CODEXIS, INC. | AGrant or award Common Stock | +40,983 | $0.00 | $0 | 137,052 | Jun 12, 2025 |
Questions about Rahul Singhvi
Answered from the filings on this page, as of the latest one.
Is Rahul Singhvi buying or selling?
Rahul Singhvi has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Rahul Singhvi's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Rahul Singhvi has 0.
Where does Rahul Singhvi file Form 4?
Rahul Singhvi has filed Form 4 at CDXS (CODEXIS, INC.); KAPA (Kairos Pharma, LTD.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.